The optimal dose and schedule of paclitaxel is not yet defined and is the subject of a number of clinical trials. These studies have not shown a clear-cut dose-response relationship. Trials evaluating administration schedule have not found either 24 h or 96 h infusion to be superior to 3 h infusion. These clinical evidence suggests that optimal dose and schedule of single-agent paclitaxel is 175 mg/m2 over 3 h. Weekly moderate-dose paclitaxel administration is generating much interest, as dose dense therapy, with very modest myelosuppression.